Tideglusib (formerly known as NP031112, NP12) is a novel, potent, irreversible, non-ATP-competitive and chemical inhibitor of GSK-3β (glycogen synthase kinase-3β) with potential neuroprotective effects and may be used as an anti-AD (Alzheimer disease) agent.

Indirubin-3′-monoxime is a novel, potent and selective inhibitor of GSK-3β (glycogen synthase kinase 3β) which also weakly inhibits 5-Lipoxygenase with IC50s of 22 nM and 7.8-10 µM, respectively; Indirubin-3′-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC50s of 100 and 180 nM.

TDZD-8 (NP01139; GSK3 Inhibitor I) is a novel, potent and non-ATP competitive GSK-3β (glycogen synthase kinase-3beta) inhibitor with the potential for treating neurodegenerative diseases such as PD (parkinson disease).

AZD2858 is a novel, potent, orally bioactive, and selective GSK-3 (glycogen synthase kinase-3) inhibitor with the potential to be used in fracture healing.

Bikinin (also known as Abrasin), a pyridinylamido compound, is a novel, potent, non-steroidal and ATP-competitive inhibitor of Arabidopsis GSK-3 (Glycogen synthase kinase 3).

KY-19382 is a novel, potent and orally active dual inhibitor of CXXC5-DVL( IC50s =19) and GSK3β( IC50s = 10 nM). It can be used for the research of high fat diet (HFD) induced metabolic diseases.

LY2090314 (LY-2090314) is a novel and potent GSK-3 (glycogen synthase kinase-3) inhibitor for GSK-3α/β with potential antitumor activity.

BRD-5648 (also known as (R)-BRD-0705) is an inactive (R)-enantiomer of BRD-0705.

9-ING-41 is a glycogen synthase kinase-3 (GSK-3) inhibitor that induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β.

GSK-3 inhibitor 1 is a novel and potent inhibitor of GSK-3 (Glycogen synthase kinase-3).